ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 274 filers reported holding ARRAY BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is 0.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $649,000 | +90.3% | 14,000 | 0.0% | 0.05% | +81.5% |
| Q1 2019 | $341,000 | +70.5% | 14,000 | 0.0% | 0.03% | +35.0% |
| Q4 2018 | $200,000 | -6.1% | 14,000 | 0.0% | 0.02% | +17.6% |
| Q3 2018 | $213,000 | -9.4% | 14,000 | 0.0% | 0.02% | -19.0% |
| Q2 2018 | $235,000 | +3.1% | 14,000 | 0.0% | 0.02% | -4.5% |
| Q1 2018 | $228,000 | – | 14,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 17,850,650 | $75,330,000 | 5.64% |
| BVF INC/IL | 6,682,711 | $28,201,000 | 4.81% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 8,729,361 | $36,838,000 | 1.49% |
| First Light Asset Management, LLC | 530,391 | $2,238,000 | 0.94% |
| KOPP INVESTMENT ADVISORS LLC | 376,477 | $1,589,000 | 0.78% |
| Sarissa Capital Management LP | 700,000 | $2,954,000 | 0.57% |
| Orbimed Advisors | 10,689,000 | $45,108,000 | 0.41% |
| Bedell Frazier Investment Counselling, LLC | 178,971 | $755,000 | 0.37% |
| PINNACLE ASSOCIATES LTD | 3,453,487 | $14,574,000 | 0.31% |
| Artal Group S.A. | 3,710,000 | $15,656,000 | 0.29% |